Portage Biotech Inc. (PRTG)

Market Cap	4.75M
Revenue (ttm)	n/a
Net Income (ttm)	-144.91M
Shares Out	19.78M
EPS (ttm)	-8.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,925
Open	0.242
Previous Close	0.253
Day's Range	0.230 - 0.264
52-Week Range	0.200 - 4.400
Beta	99.75
Analysts	Buy
Price Target	11.00 (+4,213.73%)
Earnings Date	Feb 28, 2024

About PRTG

Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1973
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTG

Analyst Forecast

According to 2 analysts, the average rating for PRTG stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 4,213.73% from the latest price.

Price Target

$11.0

(4,213.73% upside)

Analyst Consensus: Buy